Showing 3961-3970 of 5646 results for "".
- Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosahttps://modernod.com/news/endogena-therapeutics-completes-enrollment-ahead-of-schedule-in-its-phase-12a-trial-of-ea-2353-for-retinitis-pigmentosa/2481594/Endogena Therapeutics has announce that it has completed patient enrollment ahead of schedule in its phase 1/2a trial of EA-2353 for the treatment of retinitis pigmentosa (RP). With the dose-escalation stage completed in April, the ongoing trial is now in the expansion cohort stag
- Alcon Expands Plastic Bank Partnership in 2023 to Further Support Sustainability Effortshttps://modernod.com/news/alcon-expands-plastic-bank-partnership-in-2023-to-further-support-sustainability-efforts/2481591/Alcon announced the expansion of the partnership with Plastic Bank—an organization that builds recycling ecosystems in under-developed communities to fight plastic pollution while providing collection members with a path out of poverty. For each ton of plastic introduced in the marketp
- Harrow Launches Recently Acquired Products Ilevro, Nevanec, and Maxidex in the UShttps://modernod.com/news/harrow-launches-recently-acquired-products-ilevro-nevanec-and-maxidex-in-the-us/2481587/Harrow announced the completion of the transfer to Harrow of the new drug applications (NDAs) for Ilevro (nepafenac ophthalmic suspension) 0.3%, Nevanec (nepafenac ophthalmic suspension) 0.1%, and Maxidex (dexamethasone ophthalmic suspension) 0.1%. These three FDA-approved ophthalm
- Julie Schornack, OD, Named First Female President of Marshall B. Ketchum Universityhttps://modernod.com/news/julie-schornack-od-named-first-female-president-of-marshall-b-ketchum-university/2481585/Marshall B. Ketchum University (MBKU), an independent, private, non-profit, accredited educational institution in Fullerton, California has introduced Julie A. Schornack, OD, MEd, as its next president to lead the university. Dr. Schornack is the first female p
- Alcon Names Daniel M. Miller, MD, PhD, Senior Scientific Advisor to Alcon's R&D team PDFhttps://modernod.com/news/alcon-names-daniel-m-miller-md-phd-senior-scientific-advisor-to-alcons-rd-team-pdf/2481584/Alcon announced that the highly esteemed ophthalmologist, Daniel M. Miller, MD, PhD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Miller is a fellowship-trained medical and surgical retina specialist. He will serve as a Senior Scientific Advisor to Alc
- BVI Completes Enrollment of Finevision HP IDE Clinical Studyhttps://modernod.com/news/bvi-completes-enrollment-of-finevision-hp-ide-clinical-study/2481581/BVI announced it has completed enrollment of its US Investigational Device Exemption (IDE) clinical study for its latest hydrophobic trifocal IOL, Finevision HP. The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, rand
- VMG Health Acquires Healthcare Consulting Firm BSM Consultinghttps://modernod.com/news/vmg-health-acquires-healthcare-consulting-firm-bsm-consulting/2481579/VMG Health announced it has acquired BSM Consulting, a health care consulting firm with offices in Reno, Nevada and Phoenix. Financial terms of the acquisition were not disclosed. VMG Health is owned by VMG employees and Northlane Capital Partners (NCP). NCP inv
- Japanese Drugmaker Astellas Pharma Acquires Iveric Bio for $5.9 Billionhttps://modernod.com/news/japanese-drugmaker-astellas-pharma-acquires-iveric-bio-for-59-billion-1/2481577/Japan-based Astellas Pharma announced it is acquiring Iveric Bio, maker of a geographic atrophy drug in late-stage development, for $5.9 billion. Under terms of the agreement, the companies entered into a definitive agreement under which Berry Merger Sub Inc., a wholly-owned subsidiary
- Medical Consulting Group and Corcoran Consulting Group Announce Mergerhttps://modernod.com/news/medical-consulting-group-and-corcoran-consulting-group-announce-merger/2481571/Medical Consulting Group (MCG), a provider of consulting services to ophthalmic practices and companies, and Corcoran Consulting Group (CCG), a company specializing in billing, coding, and reimbursement issues for ophthalmology and optometry practices, today announced a definitive merger agreemen
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&